A prospective study suggests that the risk of liver fibrosis with methotrexate treatment has been overestimated. The findings suggest the need to reconsider the intensive strategies and the ...

Recent draft guidance highlights the challenges that industry and regulators face to predict rare drug-induced liver injury. At the end of August 2008, the consultation period ended for comments ...

The FDA slapped a boxed warning on Turalio after Daiichi saw liver toxicity in phase 3. There was no evidence of cholestatic ...

Abbisko announces positive results from phase 3 MANEUVER study of pimicotinib to treat tenosynovial giant cell tumour: Shanghai Wednesday, November 13, 2024, 18:00 Hrs [IST] Abbis ...

Merck KGaA (MKGAY.PK), a German science and technology major, announced that the Phase III MANEUVER trial of pimicotinib, an ...

The FDA informed Intercept that it is unable to approve the sNDA in its current form, consistent with the outcome of the Gastrointestinal Drugs Advisory Committee (GIDAC) meeting in September 2024. In ...

No cases of hepatotoxicity or visual disturbances were observed. Additionally, there were no clinically significant treatment ...

Following disappointing results for an antibiotic candidate whose development program is now being suspended, Spero ...

Q3 2024 Earnings Call Transcript November 12, 2024 Operator: Ladies and gentlemen, thank you for joining us today. Welcome to ...

†Data from lapatanib-treated patients with metastatic breast cancer [43,93]. ‡Data from pazopanib-treated patients with renal cell carcinoma [31]. §This is a definition of a possible Hy's law ...

BASKING RIDGE, N.J., November 13, 2024--(BUSINESS WIRE)--Daiichi Sankyo (TSE: 4568) will highlight new clinical research and ...